Hospital-based registered nurses report that fewer patients are being harmed by medical errors than was the case 10 years ago.
Hospital-based registered nurses report that fewer patients are being harmed by medical errors than was the case 10 years ago, according to a survey published in the November issue of RN magazine.
In a survey of 743 randomly selected nurses, 67% said they were not aware of any patients who had been harmed due to incompetence, physician errors or nurse errors during the month prior to the survey. In 1988, only 59% of nurses said the same.
Furthermore, 78% reported that they knew of no dangerous errors committed by unlicensed assistant personnel during the month preceding the survey.
However, when errors did occur, more nurses said they chose not to report the events to their supervisors.
Twenty-six percent of respondents said they knew of at least one physician error or incompetence that had resulted in harm to a patient, but they did not report it. Another 23% of respondents said they knew of a patient being harmed by a nurse's error but did not report it.
In 1988, the percentage of nurses who failed to report physicians' errors or incompetencies was 22%.
The percentage of nurses who failed to report serious errors made by nurses was 17% in 1988.
Why aren't nurses reporting errors as often as they used to?
Fear of reprimand or dismissal or lack of institutional support are two reasons, according to Marianne Mattera, the magazine's editor. State law does little to protect nurses who "blow the whistle" on physicians or nursing peers. Only Kentucky, Minnesota and New Jersey have laws that protect nurses from retaliation by an employer for reporting care that endangers patients.
RN magazine, a sister publication of Pharmaceutical Representative, has conducted its nursing ethics survey since 1988. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.